#1
|
|||
|
|||
Èçæîãà âî âðåìÿ áåðåìåííîñòè
33 ãîäà, áåðåìåííîñòü 30 íåäåëü, ïðîáëåì ñ ÆÊÒ âíå áåðåìåííîñòè íå èìåþ. Çàìó÷àëà èçæîãà. Ðåííè íå ïîìîãàåò âîîáùå, Ãåâèñêîí îòëè÷íî ïîìîãàåò äíåì (ïðèíèìàþ 2-4 òàáëåòêè â äåíü, â çàâèñèìîñòè îò íåîáõîäèìîñòè). Íî êàê òîëüêî ïðèíèìàþ ãîðèçîíòàëüíîå ïîëîæåíèå, èçæîãà ñòàíîâèòñÿ íåñòåðïèìîé, ïðàêòè÷åñêè äî ïîçûâîâ ê ðâîòå è íåâîçìîæíîñòè çàñíóòü. Ãåâèñêîí ïðàêòè÷åñêè íå ïîìîãàåò, ðàâíî êàê è ïðèíÿòü ïîëóñèäÿ÷åå ïîëîæåíèå, ê òîìó æå â ïîëóñèäÿ÷åì ïîëîæåíèè íà÷èíàåò áîëåòü ñïèíà.
Òî, ÷òî èìåííî ÿ åì, íà íàëè÷èå èçæîãè ïðàêòè÷åñêè íå âëèÿåò. Ïîäñêàæèòå, ïîæàëóéñòà, êàê åùå ìîæíî ïûòàòüñÿ óìåíüøèòü èçæîãó ïðè ãîðèçîíòàëüíîì ïîëîæåíèè ëåæà? Âðà÷ â êîíñóëüòàöèè íè÷åãî êðîìå Ðåííè è Ãåâèñêîíà íå ïðåäëàãàåò. |
#2
|
|||
|
|||
Ìîæíî ïîïðîáîâàòü îìåïðàçîë 10 ìã êàæäîå óòðî. Èëè æå ðàíèòèäèí.
|
#3
|
|||
|
|||
Áîëüøîå ñïàñèáî, ïîïðîáóþ!
|
#4
|
||||
|
||||
èíãèáèòîðû ïðîòîííîé ïîìïû(îìåç) íàçíà÷àþòñÿ ïðè áåðåìåííîñòè òîëüêî ïî æèçíåííûì ïîêàçàíèÿì, àíòîãîíèñòû Í2 ðåöåïòîðîâ ãèñòàìèíà(ðàíèòèäèí) ïðè áåðåìåííîñòè ïðîòèâîïîêàçàíû. Äóìàþ,äëÿ ëå÷åíèÿ èçæîãè áåðåìåííîé ýòè ïðåïàðàòû íàçíà÷àòü íå ñòîèò. Èç àíòàöèäîâ ðàçðåøåíû ôîñôàëþãåëü è, ïî íåêîòîðûì äàííûì, ìààëîêñ. Íî ,â ëþáîì ñëó÷àå,ëå÷åíèå äîëæåí íàçíà÷àòü òåðàïåâò ïðè î÷íîì îñìîòðå.
|
#5
|
|||
|
|||
Ïî÷èòàéòå ëèòåðàòóðó, óâàæàåìûé vola, îìåïðàçîë è ðàíèòèäèí óæå ðàçðåøåíû ïðè ïðèìåíåíèå ïðè áåðåìåííîñòè, åñëè ýòî íå ïåðâûé òðèìåñòð.
íàïðèìåð, âîò çäåñü, ñî ññûëêàìè íà èññëåäîâàíèÿ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#6
|
||||
|
||||
Ñîãëàñíà, ÿ è íàïèñàëà ïî æèçíåííûì ïîêàçàíèÿì,è ,åñëè Âû ñ÷èòàåòå èçæîãó áåðåìåííûõ òàêèì ïîêàçàíèåì,íàçíà÷àéòå. ß âñå æå íà÷àëà áû ñ ðåêîìåíäàöèé:ïðèïîäíÿòü èçãîëîâüå,íå ëîæèòüñÿ ñðàçó ïîñëå åäû, è íàçíà÷åíèÿ ðàçðåøåííûõ àíòàöèäîâ. Íî õî÷ó ïîâòîðèòü- ñ îáÿçàòåëüíîé î÷íîé êîíñóëüòàöèåé òåðàïåâòà äëÿ èñêëþ÷åíèÿ áîëåå ñåðüåçíîé ïàòîëîãèè ÆÊÒ.
|
#7
|
|||
|
|||
Óâàæàåìàÿ vola
Íå õî÷ó Âàì ñòàâèòü íåîäîáðÿëêó, ó Âàñ è è òàê óæå ìíîãî. ÍÎ.  óêàçàííîé ññûëêå íåò ôðàçû "ïî æèçíåííûì ïîêàçàíèÿì". Ïðî÷òèòå åùå ðàç ESOPHAGEAL REFLUX THERAPIES The following adjuvant therapies are used primarily to reduce esophageal acid reflux associated with NVP. They have all been shown to bring symptomatic relief in the non-pregnant population and are presumed to be effective in pregnancy as well. Antacids usually contain salts of magnesium, calcium, o aluminum. A wide proportion of pregnant women already use this kind of medication. These are not considered human teratogens when used in recommended doses. H2 receptor antagonists include cimetidine, ranitidine, and famotidine. Use of these medications has not been associated with an increased risk for major malformations following first trimester exposure. 16,23 Proton pump inhibitors such as omeprazole have been used in limited numbers during pregnancy. A recent study did not show an increased risk of congenital malformations.16,23 Ïàöèåíòêà óæå ïðîáîâàëà àíòàöèäû è ðàçíûé ðåæèì ïèòàíèÿ è ðàçíîå ïîëîæåíèå. Íå ïîìîãëî. Ïîêà äîéäåò äî òåðàïåâòà , âïîëíå ìîæíî íà÷àòü ïðèíèìàòü îìåïðàçîë èëè ðàíèòèäèí. |
#8
|
||||
|
||||
Êðàñíàÿ êàðòî÷êà-ïðåêðàñíûé àðãóìåíò â ëþáîé äèñêóññèè.Èíôîðìàöèÿ î÷åíü èíòåðåñíàÿ,åñëè íå òðóäíî,ïîæàëóéñòà ,óêàæèòå êàêèå èññëåäîâàíèÿ áûëè ïðîâåäåíû äëÿ ïîäòâåðæäåíèÿ îòñóòñòâèÿ òåððàòîãåííîãî ýôôåêòà,÷òîáû ÿ ìîãëà àðãóìåíòèðîâàòü íàçíà÷åíèÿ .Èçâèíèòå,ÿ - íà÷èíàþùèé ïîëüçîâàòåëü êîìï-ðà.Êîãäà íà÷èíàëà ðàáîòàòü-â õîäó åùå áûëè àðèôìîìåòðû(òàêèå øòóêè ñ ðó÷êîé äëÿ ïîäñ÷åòîâ)
|
#9
|
||||
|
||||
Óâàæàåìûé Dr.Nika, âîçâðàùàÿñü ê âîïðîñó îá èññëåäîâàíèÿõ áåçîïàñíîñòè íàçíà÷åíèÿ îìåïðîçîëà è ðàíèòèäèíà áåðåìåííûì : âîò ñòàòüÿ â æóðíàëå" Ëå÷àùèé âðà÷" àïðåëü 2009 ,àâòîðû êìí Ò.Á.Åëîõèíà è äìí Â.Ë.Òþòþííèê. Àâòîðû óêàçûâàþò,÷òî ïî êëàññèôèêàöèè FDA îìåïðàçîë îòíîñèòñÿ ê êàòåãîðèè Â, à ðàíèòèäèí,âîîáùå Ñ...è "åäèíñòâåííîé áåçîïàñíîé ãðóïïîé ÿâëÿþòñÿ àíòàöèäû"
|
#10
|
|||
|
|||
Ïîñìîòðèòå â ýòîé ñòàòüå
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] òàì äàíû ññûëêè íà èññëåäîâàíèÿ È õîòÿ FDA íå ñìåíèëî êàòåãîðèþ Ñ äëÿ îìåïðàçîëà, íî äàííûõ îêàçàëîñü äîñòàòî÷íî, ÷òîáû àìåðèêàíñêàÿ àññîöèàöèÿ àêóøåð ãèíåêîëîãîâ âêëþ÷èëà îìåïðàçîë äëÿ ñèìïòîìàòè÷åñêîãî ëå÷åíèÿ èçæîãè è ðåôëþêñà ïðè áåðåìåííîñòè (ýòî äëÿ ïðèìåðà, â ãàéäàõ äðóãèõ ñòðàí òîæå îìåïðàçîë óæå âêëþ÷åí). À ðàíèòèäèí äàâíî óæå â ãàéäàõ ôèãóðèðóåò, ãäå òî âèäåëà, ÷òî áîëåå 30 ëåò. |
#11
|
|||
|
|||
Ïðè âñåì óâàæåíèè ê æóðíàëó "Ëå÷àùèé âðà÷", íå ìîãó ñîãëàñèòüñÿ ñ òåì, ÷òî èõ èíôîðìàöèÿ âåðíà.
Âîò ïîñëåäíèé äîêóìåíò ñ ñàéòà FDA ïî îìåïðàçîëó [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ãîâîðÿò, ÷òî No increased risk of adverse pregnancy outcome demonstrated À ó ðàíèòèäèíà óæå äàâíî êàòåãîðèÿ Â |